Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHW5FT)

Drug Name
2-(5-fluoro-1H-indol-3-yl)ethanamine Drug Info
Synonyms
5-Fluorotryptamine; 576-16-9; 3-(2-Aminoethyl)-5-fluoro-1H-indole; 1H-Indole-3-ethanamine, 5-fluoro-; 2-(5-FLUORO-1H-INDOL-3-YL)ETHAN-1-AMINE; 2-(5-Fluoro-1H-indol-3-yl)ethylamine; CHEMBL275628; 2-(5-Fluoro-1H-indol-3-yl)-ethylamine; 2-(5-fluoroindol-3-yl)ethylamine; PubChem1926; PubChem13384; ChemDiv2_003993; AC1L4V8Y; AC1Q4NE7; Oprea1_696214; GTPL146; SCHEMBL387663; 5-fluorotryptamine, AldrichCPR; cid_197774; CTK5A7173; ZINC77278; BDBM30853; DTXSID20206229; ZKIORVIXEWIOGB-UHFFFAOYSA-N; 5-fluorotryptamine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
164682
CAS Number
CAS 576-16-9
TTD Drug ID
DMHW5FT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Long transient receptor potential channel 8 (TRPM8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Menthol DMG2KW7 Back pain ME84.Z Approved [5]
D-3263 DM7V2OM Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
PF-05105679 DM4QPT0 Pain MG30-MG3Z Phase 1 [7]
2-APB DM9AKVR Discovery agent N.A. Investigative [8]
ACAA DMACYPW Discovery agent N.A. Investigative [9]
5-METHOXYTRYPTAMINE DMARCKD Discovery agent N.A. Investigative [3]
icilin DMYVOL9 Discovery agent N.A. Investigative [10]
NADA DM3ORGM Discovery agent N.A. Investigative [9]
2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine DMD2QVO Discovery agent N.A. Investigative [3]
linalool DMGZQ5P Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1E receptor (HTR1E)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [2]
5-CT DM260KD Discovery agent N.A. Investigative [2]
TFMPP DMAC8TP Discovery agent N.A. Investigative [2]
1-naphthylpiperazine DM6BIWK Discovery agent N.A. Investigative [2]
BRL-15572 DMM61Y2 Discovery agent N.A. Investigative [12]
2-methyl-5-HT DM1S5CB N. A. N. A. Investigative [13]
alpha-methyl-5-HT DMCAYXF Discovery agent N.A. Investigative [2]
m-chlorophenylpiperazine DMM1J2D Discovery agent N.A. Investigative [2]
EDMT DMS3AXK Discovery agent N.A. Investigative [14]
9-OH-risperidone DMGORXQ Discovery agent N.A. Investigative [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [16]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [16]
Etoricoxib DM6A4NW Rheumatoid arthritis FA20 Approved [16]
Capsaicin DMGMF6V Back pain ME84.Z Approved [17]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [18]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [19]
Nifedipine DMSVOZT Angina pectoris BA40 Approved [20]
Zileuton DMVRIC2 Allergic asthma CA23.0 Approved [21]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [22]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fomepizole DM6VOWQ Athylene glycol or methanol poisoning NE61 Approved [24]
Ademetionine DMYQDBO Hepatic fibrosis DB93.0 Approved [25]
Theophylline DMRJFN9 Bronchitis CA20 Approved [23]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [26]
Ethanol DMDRQZU Chronic pain MG30 Approved [27]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [28]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [29]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [30]
Didanosine DMI2QPE Human immunodeficiency virus infection 1C62 Approved [23]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [32]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [33]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [32]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [33]
Sulfinpyrazone DMEV954 Gout FA25 Approved [34]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [32]
Zafirlukast DMHNQOG Asthma CA23 Approved [32]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [32]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [35]
Dabrafenib DMX6OE3 Melanoma 2C30 Approved [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [37]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [38]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [39]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [40]
Oxatomide DM1F42Z Hay fever CA08.00 Approved [41]
Cinacalcet DMCX0K3 Hyperparathyroidism 5A51 Approved [42]
Capsaicin DMGMF6V Back pain ME84.Z Approved [17]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [43]
Quinidine DMLPICK N. A. N. A. Approved [44]
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [46]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [47]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [43]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [48]
Capsaicin DMGMF6V Back pain ME84.Z Approved [17]
Zafirlukast DMHNQOG Asthma CA23 Approved [49]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [43]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [50]
Fluconazole DMOWZ6B Cryptococcal meningitis Approved [48]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [4]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [51]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [52]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [53]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [54]
Clopidogrel DMOL54H Acute coronary syndrome BA41 Approved [55]
Artemisinin DMOY7W3 Malaria 1F40-1F45 Approved [56]
Malathion DMXZ84M Pediculus capitis infestation 1G00.0 Approved [57]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [58]
Permethrin DMZ0Q1G Pediculus capitis infestation 1G00.0 Approved [59]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [46]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [31]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [48]
Chloramphenicol DMFXEWT Bacterial infection 1A00-1C4Z Approved [4]
Capsaicin DMGMF6V Back pain ME84.Z Approved [17]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [43]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [19]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [43]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [31]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [23]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1E receptor (HTR1E) TTCPG9S 5HT1E_HUMAN Agonist [2]
Long transient receptor potential channel 8 (TRPM8) TTXDKTO TRPM8_HUMAN Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Gene/Protein Processing [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 146).
2 Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
3 5-benzyloxytryptamine as an antagonist of TRPM8. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7076-9.
4 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
5 TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10.
6 Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009 Spring; 11(2): 82-107.
7 Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans. J Pharmacol Exp Ther. 2014 Nov;351(2):259-69.
8 Effects of antagonists and heat on TRPM8 channel currents in dorsal root ganglion neuron activated by nociceptive cold stress and menthol. Neurochem Res. 2012 Feb;37(2):314-20.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 500).
10 Evolution of thermal response properties in a cold-activated TRP channel. PLoS One. 2009 May 29;4(5):e5741.
11 Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
12 SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
13 Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
14 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
15 Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
16 In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
17 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
18 Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
19 Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
20 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
21 Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
22 Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
23 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
24 Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
25 Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
26 Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
27 An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
28 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
29 Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
30 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
31 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
32 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
33 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
34 Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
35 Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
36 Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
37 Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
38 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
39 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
40 Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
41 Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
42 Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
43 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
44 Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
45 Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
46 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
47 Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
48 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
49 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
50 The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
51 Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
52 Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
53 Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
54 Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
55 Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
56 Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
57 Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
58 Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
59 Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.